SCHEMBL1307153

SCHEMBL1307153

O=[C]NC1CCN(CCO)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.41
PKM P14618 1/20 0.40
KMT2A Q03164 1/20 0.40
SLC18A3 Q16572 1/20 0.40
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HTR4 Q13639 2/20 0.35
F2 P00734 1/20 0.34
ST14 Q9Y5Y6 1/20 0.34
SLC6A5 Q9Y345 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
HSD11B1 P28845 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CARM1 Q86X55 1/20 0.32
PRMT6 Q96LA8 1/20 0.32
POLB P06746 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3954240 0.89 SLC6A5 (0.36) KDM1APKMKMT2ASLC18A3HTR4
SCHEMBL1781485 0.77 KDM1A (0.45) KDM1AHTR4SMN1; SMN2HSD11B1POLB
SCHEMBL1781918 0.76 SMN1; SMN2 (0.42) KMT2AALDH1A1KDM4ESMN1; SMN2HSD11B1
SCHEMBL3412663 0.74 KDM1A (0.44) KDM1APKMKMT2ASLC18A3ALDH1A1
SCHEMBL3947563 0.74 SLC18A3 (0.43) KDM1APKMKMT2ASLC18A3ALDH1A1
SCHEMBL1921058 0.73 KMT2A (0.47) KDM1APKMKMT2ASLC18A3HTR4
SCHEMBL1307156 0.73 ADH1B (0.48) KDM1APKMKMT2ASLC18A3ALDH1A1
SCHEMBL3947898 0.73 HTR2A (0.38) ALDH1A1
SCHEMBL769922 0.73 POLB (0.37) KDM1AALDH1A1KDM4EPOLB
SCHEMBL1516839 0.72 KDM1A (0.43) KDM1APKMKMT2ASLC18A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US claimed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US claimed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP claimed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO claimed
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US disclosed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US disclosed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP disclosed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 KDM1A 1127/4885PKM 1672/4885KMT2A 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.